Treatment patterns and outcomes in neuroendocrine tumors
Part of Cancer, Digestive system clinical trials.
This study examines how doctors treat gastroenteropancreatic neuroendocrine tumors (rare slow-growing cancers of the stomach, pancreas, or intestines) and how patients respond. Researchers will review medical records from 2018–2025 to understand which treatments work best and help improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a diagnosis of gastroenteropancreatic neuroendocrine tumor (GEP-NET) between January 2018 and December 2025
- Have started your first treatment for GEP-NET (such as somatostatin analogs, targeted therapy, radiation therapy, or chemotherapy) on or after your diagnosis date
- Be 18 years or older when you started treatment
- Have continuous health insurance coverage for at least 12 months before starting treatment
- Have at least 1 month of health insurance coverage and medical/pharmacy records after starting treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the nutritional health of people with a type of digestive tumor called a neuroendocrine tumor. It aims to understand how these tumors affect nutrition, which could help doctors improve care.
This trial studies whether it’s helpful to keep taking somatostatin “analog” injections even after your neuroendocrine tumor has started growing despite the usual dose. It also looks at how the next treatment choice (targeted pills or PRRT) fits in for people with non-functional, well-differentiated GEP NET.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
This study keeps a worldwide record of people with neuroendocrine tumors to learn about care patterns and outcomes. It may help your doctors and future patients by improving how these tumors are monitored and treated.
This study looks at how tumor and patient factors affect treatment response in well-differentiated GEP-NENs (neuroendocrine tumors of the digestive system). It may help doctors understand which treatments work best for people like you.
Hear when a new Gastroenteropancreatic Neuroendocrine Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.